Yabao Pharmaceutical Group Co (SHSE:600351) Accounts Payable: ¥142 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600351 Yabao Pharmaceutical Group Co Ltd SHSE:600351
64 GF Score
Price ¥6.66
GF Value ¥5.71
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Yabao Pharmaceutical Group Co Accounts Payable?

Yabao Pharmaceutical Group Co SHSE:600351 -1.48% 64 Accounts Payable is ¥142 Mil as of Jun. 2026. GuruFocus rates SHSE:600351 with a GF Score™ of 64/100 and a GF Value™ of ¥5.71 (Modestly Overvalued). The stock has 3 warning signs investors should review.

Yabao Pharmaceutical Group Co's Accounts Payable for the quarter that ended in Jun. 2026 was ¥142 Mil.

Yabao Pharmaceutical Group Co's quarterly Accounts Payable increased from Dec. 2025 (¥127 Mil) to Mar. 2026 (¥130 Mil) and increased from Mar. 2026 (¥130 Mil) to Jun. 2026 (¥142 Mil).

Yabao Pharmaceutical Group Co's annual Accounts Payable declined from Dec. 2023 (¥222 Mil) to Dec. 2024 (¥183 Mil) and declined from Dec. 2024 (¥183 Mil) to Dec. 2025 (¥127 Mil).

Yabao Pharmaceutical Group Co Accounts Payable Related Terms

Yabao Pharmaceutical Group Co Accounts Payable Historical Data

* Premium members only.

The historical data trend for Yabao Pharmaceutical Group Co's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yabao Pharmaceutical Group Co Accounts Payable Chart

Yabao Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 151.46 197.58 221.53 182.54 126.51

Yabao Pharmaceutical Group Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 132.09 116.21 126.51 129.61 142.11
SHSE:600351
64GF Score
Yabao Pharmaceutical Group Co Ltd SHSE:600351
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Yabao Pharmaceutical Group Co Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of ¥142 Mil mean?
Yabao Pharmaceutical Group Co (SHSE:600351) has a Accounts Payable of ¥142 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Yabao Pharmaceutical Group Co and its competitors.
Is Yabao Pharmaceutical Group Co's Accounts Payable too high?
Yabao Pharmaceutical Group Co's current Accounts Payable is ¥142 Mil. Overall, Yabao Pharmaceutical Group Co has a GF Score™ of 64/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Yabao Pharmaceutical Group Co's Accounts Payable compare to ZTS?
Yabao Pharmaceutical Group Co's Accounts Payable of ¥142 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Yabao Pharmaceutical Group Co and its competitors. Yabao Pharmaceutical Group Co's current Accounts Payable is ¥142 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yabao Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Yabao Pharmaceutical Group Co (SHSE:600351) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥5.71, compared to a current price of ¥6.66 — trading 16.6% above its estimated fair value. The current Accounts Payable is ¥142 Mil. Yabao Pharmaceutical Group Co's overall GF Score™ is 64/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Yabao Pharmaceutical Group Co (SHSE:600351), the current Accounts Payable is ¥142 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Yabao Pharmaceutical Group Co (SHSE:600351) Overvalued in 2026?

Based on GuruFocus' analysis, Yabao Pharmaceutical Group Co stock appears to be overvalued. The current stock price of ¥6.66 is trading 16.6% above its estimated GF Value™ of ¥5.71. GuruFocus considers Yabao Pharmaceutical Group Co to be Modestly Overvalued.

Key valuation signals for SHSE:600351:

  • Accounts Payable: ¥142 Mil
  • GF Value™: ¥5.71 vs. price of ¥6.66 (16.6% above fair value)
  • GF Score™: 64/100 with 3 warning signs

No single metric tells the full story. See the SHSE:600351 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Yabao Pharmaceutical Group Co Business Description

Address No.43 Fumin Road, Ruicheng, Shanxi Province, Yuncheng, CHN, 044602
Yabao Pharmaceutical Group Co Ltd is engaged in the manufacture and operation of western and Chinese medicines, APIs, health care products, packing materials for medicine, and also engages in the planting and processing of medicinal herbs.
64GF Score

Get the complete analysis for SHSE:600351

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥6.66
Price
¥5.71
GF Value